Steven Quayle
Senior Vice President, Head of Research & Translational Medicine Cue Biopharma
Steven Quayle is Senior Vice President and Head of Research & Translational Medicine at Cue Biopharma, where he leads the advancement of the company’s Immuno-STAT™ platform to develop selective immune modulators for the treatment of autoimmune diseases and cancer.
Seminars
Thursday 11th December 2025
Development of Novel Biologics that Promote T Cell-Mediated Depletion of Pathogenic Cell Types in Autoimmune Disease
2:30 pm
- Introduction to the Immuno-STAT™ platform for selective regulation of antigen-specific T cells
- Lead candidate CUE-501 differentiates from pan-TCEs by selectively engaging existing virus-specific T cells to deplete pathogenic B cells while minimising systemic immune activation and CRS risk
- The modularity of the Immuno-STAT™ platform enables opportunities to target additional pathogenic cell types beyond B cells and opens avenues for novel therapeutic approaches in autoimmunity and oncology
